Benitec Biopharma (NASDAQ:BNTC) Stock Price Expected to Rise, HC Wainwright Analyst Says

Benitec Biopharma (NASDAQ:BNTC) had its price objective increased by stock analysts at HC Wainwright from $28.00 to $35.00 in a research note issued on Tuesday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 121.80% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 target price (down previously from $35.00) on shares of Benitec Biopharma in a research note on Tuesday, September 16th. Wall Street Zen raised Benitec Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, October 25th. JMP Securities set a $22.00 target price on Benitec Biopharma in a research note on Tuesday. Citizens Jmp upped their target price on Benitec Biopharma from $20.00 to $22.00 and gave the company a “market outperform” rating in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Benitec Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $25.83.

Benitec Biopharma Price Performance

Shares of NASDAQ:BNTC opened at $15.78 on Tuesday. The business’s 50 day simple moving average is $14.54 and its 200-day simple moving average is $13.79. The firm has a market capitalization of $414.23 million, a price-to-earnings ratio of -10.73 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 54.67 and a quick ratio of 54.67. Benitec Biopharma has a 12 month low of $9.10 and a 12 month high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.18). As a group, equities analysts forecast that Benitec Biopharma will post -1.48 earnings per share for the current fiscal year.

Institutional Trading of Benitec Biopharma

Several large investors have recently added to or reduced their stakes in the stock. MYDA Advisors LLC grew its stake in shares of Benitec Biopharma by 4.0% during the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock valued at $677,000 after acquiring an additional 2,000 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Benitec Biopharma during the second quarter valued at about $38,000. Bank of America Corp DE grew its stake in shares of Benitec Biopharma by 2,255.8% during the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 6,587 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Benitec Biopharma during the second quarter valued at about $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Benitec Biopharma during the second quarter valued at about $93,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.